Streetbeat News

Products Services

RZLT

Rezolute, Inc. (NASDAQ:RZLT) has received FDA clearance for its Investigational New Drug (IND) application for RZ358 to treat hypoglycemia in patients with tumor hyperinsulinism. The company plans to start patient enrollment in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:31 am

GOOGL

META

MSFT

NVDA

Nvidia's advanced AI chips are reportedly being smuggled into China, bypassing U.S. trade restrictions, potentially aiding the Chinese military. The Biden administration plans to broaden its export ban to other countries. Nvidia is developing a compliant chip for the Chinese market, but production delays are affecting major clients.

Portfolio Pulse from Navdeep Yadav

August 05, 2024 | 11:31 am

ALZN

Alzamend Neuro aims to compare lithium levels in the human brain to identify an ideal dose of AL001 that is both safe and effective, potentially improving current products.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:30 am

ALZN

Alzamend Neuro Inc. (NASDAQ:ALZN) is conducting a Phase 2 clinical trial of its Alzheimer's candidate AL001 in partnership with Massachusetts General Hospital. The trial aims to compare AL001's effectiveness and safety against a commonly marketed lithium salt. The study will help meet FDA regulatory safety standards and could lead to a next-generation lithium product with an improved safety profile. Alzamend previously completed a Phase 2A trial identifying a maximum tolerated dose for AL001. The company also terminated its 'at-the-market' equity offering program to preserve shareholder value.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 11:30 am

ALZN

Alzamend Neuro announced a head-to-head study of its AL001 product versus a marketed lithium carbonate product.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:30 am

ALZN

Alzamend Neuro has partnered with Massachusetts General Hospital for a Phase II trial of AL001, targeting Alzheimer's disease patients.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:30 am

DIS

IMAX

SPY

VOO

Walt Disney Co (NYSE:DIS) and Marvel Studios' 'Deadpool & Wolverine' grossed $824 million globally after two weekends, contributing to Disney surpassing $3 billion in worldwide ticket sales in 2024. The film has also performed well in premium formats like Imax Corp (NYSE:IMAX). Disney's stock closed lower by 3.74%, while IMAX closed higher by 0.57%.

Portfolio Pulse from Anusuya Lahiri

August 05, 2024 | 11:29 am

GOOG

GOOGL

META

MSFT

NVDA

NVDL

SMH

SOXL

SOXX

USD

Chip stocks-linked ETFs, including SOXL, NVDL, USD, SMH, and SOXX, experienced significant declines in pre-market trading amid a global market downturn. The drop is attributed to recession fears sparked by a disappointing U.S. jobs report and Nvidia's production delays.

Portfolio Pulse from Benzinga Neuro

August 05, 2024 | 11:27 am

ASTS

AST SpaceMobile has received FCC approval to launch its first five commercial BlueBird satellites, marking a significant milestone for its space-based cellular network. The license allows AST SpaceMobile to operate various frequencies for essential satellite operations.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:16 am

ATNM

The FDA has determined that Actinium Pharmaceuticals' Phase 3 Sierra Trial is not adequate to support a BLA filing for Iomab-B for relapsed or refractory acute myeloid leukemia, despite achieving its primary endpoint. Actinium will need to conduct an additional head-to-head randomized clinical trial to demonstrate overall survival benefit. The company plans to request a meeting with the FDA to discuss the specifics and will seek a strategic partner for Iomab-B in the U.S. Actinium will also focus on developing Actimab-A, Iomab-ACT, and preclinical programs.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 11:12 am